Merck Sharp + Dohme Corp.

Metabasis Therapeutics, Inc.

Baruch S. Blumberg Institute

Drexel University

Schering-plough Corporation

Schering Corporation

Pharmacopeia Inc.

Huagang Lu

Qun Dang

Jianming Bao

F Anthony Romero

Iyassu Sebhat

Dariusz Wodka

Ping Lan

Hongjian Jiang

Tony Gibson

De Michael Chung

Gergely M Makara

Jinlong Jiang

Brett C Bookser

Ahmet Kekec

Andrea Cuconati

Daniel Cashion

David Wilson

Andy Kassick

Neng-Yang Shih

William Alvin Kinney

Robert G Aslanian

Kevin D McCormick

Timothy Michael Block

Christopher W Boyce

Pietro Mangiaracina

Xiaodong Xu

Chia-Yu Huang

Ju-Tao Guo

Yanming Du

Bo Liang

Salem Fevrier

Haitao Guo

Rong-qiang Liu

Dawei Cai

John Rogowsky

Daniel K Cashion

Pietro Mangiarcina

Described herein are substituted aminothiazoles, compositions comprising same; and methods of making and using same.

Substituted aminothiazoles

Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA.

Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

Cyclic benzimidazole derivatives useful as anti-diabetic agents

Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, Metabolic Syndrome, obesity, hypercholesterolemia, and hypertension.

In its many embodiments, the present invention provides a novel class of indolines as inhibitors of &#x3b1;2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the &#x3b1;2C adrenergic receptors using such compounds or pharmaceutical compositions.

Functionally selective alpha2C adrenoreceptor agonists

Growing community of inventors

Plainsboro, NJ, United States of America

Huagang Lu